Production (Stage)
LAVA Therapeutics N.V.
LVTX
$1.32
$0.021.54%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 1,313.60% | -- | -- | 471.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 1,313.60% | -- | -- | 471.24% |
| Cost of Revenue | -- | -24.95% | -- | -- | -- |
| Gross Profit | -- | 39.56% | -- | -- | 2,278.23% |
| SG&A Expenses | 1.54% | 21.84% | -2.55% | -18.18% | -13.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.95% | 37.90% | 4.68% | -49.90% | -38.85% |
| Operating Income | -272.69% | 42.75% | -5.20% | 30.89% | 84.96% |
| Income Before Tax | -503.71% | 43.52% | -38.86% | 34.85% | 96.11% |
| Income Tax Expenses | 226.09% | 874.36% | 92.00% | -12.37% | -2.82% |
| Earnings from Continuing Operations | -472.20% | 37.92% | -39.16% | 34.68% | 95.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -472.20% | 37.92% | -39.16% | 34.68% | 95.64% |
| EBIT | -272.69% | 42.75% | -5.20% | 30.89% | 84.96% |
| EBITDA | -295.40% | 42.47% | -5.62% | 31.00% | 85.89% |
| EPS Basic | -470.04% | 38.13% | -36.27% | 35.98% | 95.72% |
| Normalized Basic EPS | -1,459.52% | 104.85% | -35.95% | 36.15% | 96.18% |
| EPS Diluted | -470.04% | 38.13% | -36.27% | 35.98% | 95.72% |
| Normalized Diluted EPS | -1,459.52% | 104.85% | -35.95% | 36.15% | 96.18% |
| Average Basic Shares Outstanding | 0.37% | 0.36% | 2.12% | 2.03% | 1.92% |
| Average Diluted Shares Outstanding | 0.37% | 0.36% | 2.12% | 2.03% | 1.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |